LONDON--(BUSINESS WIRE)--Apr 15, 2019--The global Lennox-Gastaut syndrome (LGS) treatment market is expected to post a CAGR of close to 5% during the period 2019-2023, according to the latest market research report by Technavio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190415005072/en/
The global Lennox-Gastaut syndrome (LGS) treatment market will post a CAGR of close to 5% during the period 2019-2023 (Graphic: Business Wire)
LGS is a rare, refractory, debilitating type of epilepsy with life-threatening consequences in pediatric patients. The treatment for LGS rely on the seizure type and requires a broad spectrum of anti-epileptic drugs. The identification of LGS in the early stages helps in treating it more effectively. As a result, many government and non-government organizations are taking initiatives to increase the awareness of the early diagnosis and treatment of LGS across the world. For instance, the National Organization for Rare Disorders (NORD) and Genetic and Rare Diseases (GARD) Information Center are raising awareness about the signs and symptoms, causes, diagnosis, and standard treatment of LGS in the US. Hence, the increase in the number of organizations that create awareness about LGS will propel the growth of the LGS treatment market during the forecast period.
As per Technavio, advances in surgical treatments will have a positive impact on the market and contribute to its growth significantly over the forecast period. This global Lennox-Gastaut syndrome treatment market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
Global Lennox-Gastaut syndrome treatment market: Advances in surgical treatments
Corpus callosotomy is a palliative surgical procedure which has been commonly used to treat patients with generalized seizures including drop attacks due to LGS. However, callosotomy involves craniotomy with microdissection. Hence, to overcome the downsides of corpus callosotomy, many companies are introducing novel minimally invasive methods for performing the surgical ablation of epileptogenic foci. For instance, MR-guided laser interstitial thermal therapy (MRg-LITT) was introduced recently, which can be used as a minimally invasive method for performing the surgical ablation of epileptogenic foci and corpus callosotomy. Such advances in surgical treatments will fuel the growth of the global LGS treatment market during the forecast period.
“The number of patients with medical conditions such as trauma, stroke, perinatal hypoxia, tuberous sclerosis, and cortical dysplasia is increasing significantly. Congenital infections and infections to the central nervous system, such as encephalitis and meningitis, are also increasing which are major risk factors for LGS. This rise in the number of patients with these risk factors is increasing the prevalence of LGS, thereby driving the growth of the LGS treatment market” says a senior research analyst at Technavio.
Global Lennox-Gastaut syndrome treatment market: Segmentation analysis
This market research report segments the global Lennox-Gastaut syndrome treatment market by type (surgical treatment and non-surgical treatment) and geography (North America, Europe, Asia, and ROW).
The non-surgical treatment segment held the largest Lennox-Gastaut syndrome treatment market share in 2018. The growth of the non-surgical treatment segment can be attributed to the recent drug approvals for the treatment of LGS and the adoption of a ketogenic diet.
The North America region led the market in 2018, followed by Europe, Asia, and ROW respectively. North America dominated the global LGS treatment market owing to the rising awareness of LGS and the increase in funding for the research on LGS in this region. Also, the strategic alliances among organizations that promote awareness about LGS are also supporting the growth of the market in the region.
Looking for more information on this market?Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market size and forecast
Five Forces Analysis
- Regional comparison
- Key leading countries
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190415005072/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: SURGERY HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2019.
PUB: 04/15/2019 10:04 AM/DISC: 04/15/2019 10:04 AM